1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
August 2009 in “Australian Prescriber” Eculizumab was a humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria by binding to complement protein C5, thereby reducing hemolysis and stabilizing hemoglobin levels. In a study with 87 patients, 49% of those treated with eculizumab had stabilized hemoglobin levels, and 51% did not require blood transfusions, unlike the placebo group, where all needed transfusions. An open-label study with 97 patients showed suppressed hemolytic activity in 89 patients, reducing transfusion needs. However, eculizumab increased susceptibility to meningococcal infections, requiring vaccination before treatment. While it reduced thromboembolism rates, the long-term outcomes and effects on survival were uncertain, and the high cost of the drug was a concern.
1 citations
,
January 2018 in “Skin appendage disorders” The complement system might be involved in the development of alopecia areata and could lead to new treatments.
July 2017 in “Clin-Alert” Different medications can cause serious side effects in some people.